Beijing's premier biotechnology company, Sinovac Biotech has entered into an exclusive promotion service agreement with GlaxoSmithKline China Investment. GSK China and Sinovac will market and promote Anflu, a seasonal influenza vaccine developed and manufactured by Sinovac. GSK China's sales team will focus on the distribution of the adult dosage formulation and Sinovac will sell the pediatric dosage formulation.
Mr Weidong Yin, President and CEO of Sinovac, said, "This collaboration with GSK China will leverage the strengths of the two companies' sales and marketing teams, creating synergy for the distribution of Anflu. Seizing this partnering opportunity with a well-known, global pharmaceutical company represents a significant step for Sinovac. We will continue to execute this strategy in order to increase shareholder value."
Ms Amy Huang, Area Director for GSK China/HK, said, "This agreement reflects GSK's willingness to work with local partners to take on this challenge. Sinovac is one of the most active Chinese vaccine manufacturers, in both seasonal and pandemic flu franchises, and we anticipate a lot of synergy between GSK and Sinovac. GSK remains committed to do more for the Chinese people, and help the people of China feel better and live longer."